

Nevada DUR Board Meeting  
June 19, 2003  
Minutes

Attendees: Lori Winchell, Dave England, Joseph Johnson, colleen Lawrence, Leslie Parrick and Anita Sheard

Visitors: Steve Espy, Health Information Designs

Earle Johnson, Dir of NV Medicaid Operations, First Health

Jeff Monaghan, Pharmacy Manager, First Health

Nancy Davis, First Health

Davis Shestak, Dir State Gov Affairs for Johnson & Johnson

Alan Sloan, Purdue Pharma

Kathryn Keller, Purdue Pharma

Dave England brought the meeting to order at 1:00pm

Joseph Johnson moved and Lori Winchell seconded the minutes be approved, the motion carried.

Steve Espy reviewed the quarterly reports that were made available in the Board packet.

Duragesic review: Coleen Lawrence asked the Board to consider excluding patients with a cancer diagnosis from the prior approval limits on Duragesic. There was discussion and public comment, the Board decided to table the consideration until they can review utilization data that will be provided to them.

J codes review: colleen Lawrence asked the Board to review the list of J codes that are in the packet and consider which codes may need to have a prior approval placed on them. The Board is to decide on the codes at the next Board meeting.

Legislative update: Coleen Lawrence announced that bill number AB384 passed through the legislature. This bill will allow for a P&T committee and the creation of a Preferred Drug List. The bill will also allow DHCFP to seek supplemental rebates from manufactures who want to place their drugs on the Preferred Drug List.

Medicaid update: Coleen Lawrence announced that the implementation of the MMIS system is progressing and will be fully operational by 9/1/03.

Public Comment: Kathryn Keller, Purdue Pharma read a statement in regards to the limits that are currently on Oxycontin.

The next meeting is set for September 18, 2003.